ANI Pharmaceuticals reports outcomes from diabetic macular oedema trial
Summary by Clinical Trials Arena
1 Articles
1 Articles
ANI Pharmaceuticals reports outcomes from diabetic macular oedema trial
ANI Pharmaceuticals has disclosed the outcomes of its NEW DAY trial, assessing Iluvien 0.19mg, in people with diabetic macular oedema.The post ANI Pharmaceuticals reports outcomes from diabetic macular oedema trial appeared first on Clinical Trials Arena.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium